Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Brain Neoplasms 6Breast Neoplasms 4Recurrence 2Oligodendroglioma 2Meningeal Carcinomatosis 2Glioblastoma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Meningeal Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × paclitaxel-Angiopep-2 conjugate × Clear all
NCT02048059 2020-02-25

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Angiochem Inc

Phase 2 Completed
72 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡